DRACO Down the Memory Hole
They had a cure over a decade ago, but not for you
Double-stranded RNA Activated Caspase Oligomerizer
On July 27th, 2011, a paper was published in PLOS ONE describing a novel protein biologic antiviral. It was called DRACO, an acronym for Double-stranded RNA Activated Caspase Oligomerizer.
PLOS - Broad-Spectrum Antiviral Therapeutics
Currently there are relatively few antiviral therapeutics, and most which do exist are highly pathogen-specific or have other disadvantages. We have developed a new broad-spectrum antiviral approach, dubbed Double-stranded RNA (dsRNA) Activated Caspase Oligomerizer (DRACO) that selectively induces apoptosis in cells containing viral dsRNA, rapidly killing infected cells without harming uninfected cells. We have created DRACOs and shown that they are nontoxic in 11 mammalian cell types and effective against 15 different viruses, including dengue flavivirus, Amapari and Tacaribe arenaviruses, Guama bunyavirus, and H1N1 influenza. We have also demonstrated that DRACOs can rescue mice challenged with H1N1 influenza. DRACOs have the potential to be effective therapeutics or prophylactics for numerous clinical and priority viruses, due to the broad-spectrum sensitivity of the dsRNA detection domain, the potent activity of the apoptosis induction domain, and the novel direct linkage between the two which viruses have never encountered.
Funding: This work is funded by grant AI057159 (http://www.niaid.nih.gov/Pages/default.aspx) from the National Institute of Allergy and Infectious Diseases and the New England Regional Center of Excellence for Biodefense and Emerging Infectious Diseases, with previous funding from the Defense Advanced Research Projects Agency, Defense Threat Reduction Agency, and Director of Defense Research & Engineering. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the United States government.
This research was performed at MIT’s Lincoln Labs and then moved into the Draper Laboratory and was funded by NIAID, DARPA, and DTRA. The Pentagon were after a broad-spectrum antivirus that could cure any viral infection, in case soldiers were exposed to an unknown pathogen for which no vaccine existed (i.e. a biowarfare agent). Dr. Todd Rider’s solution was to come up with a chimeric protein consisting of a dsRNA detection domain fused end-to-end with an apoptosis induction domain. These protein biologics were produced by being cultured in a bioreactor in E. Coli bacteria transfected with plasmids to produce DRACO proteins, similar to how recombinant insulin is produced.
It is possible to formulate different types of DRACOs, such as Protein Kinase R and Apoptotic protease activating factor-1, PKR and FADD, RNaseL and Apaf-1, et cetera. DRACOs all have the same mechanism of action. They take advantage of the fact that many viruses, including coronaviruses, produce long strands of dsRNA when they infect cells and replicate. Even viruses with ssRNA genomes like SARS-CoV-2 do this. Healthy cells, on the other hand, don’t have any long strands of dsRNA in them at all.
This is how it works:
DRACO proteins are injected into the subject.
The proteins use cell-penetrating peptides (like HIV TAT) to cross cell membranes and enter cells.
If there is no viral dsRNA present, the protein does nothing.
If there is viral dsRNA present, the dsRNA detection domain (such as PKR) binds to the dsRNA.
Multiple DRACOs bind side-by-side to the viral dsRNA.
The exposed apoptosis induction domains of the DRACOs (such as Apaf-1) bind and crosslink procaspases and force the infected cell to self-destruct.
DRACOs are like little protein limpet mines that enter infected cells and command those cells to undergo apoptosis immediately if they find signs of viral infection, but are non-toxic to healthy tissue. This was proven experimentally in mouse models. They injected mice with DRACO, and then injected them with large quantities of influenza virus. Nothing happened to the DRACO treated mice when they were exposed to influenza. They were fine. In fact, they dissected the healthy DRACO-treated mice and confirmed that the DRACO proteins were non-toxic to uninfected cells.
DRACO proteins conferred practically ironclad protection against viruses that lasted up to a week after injection. All viruses. You see, viruses have ways of suppressing apoptosis pathways in cells, turning infected cells into practical zombies that can’t quite eliminate themselves before they replicate tons of viral particles. It makes a real mess. However, a protein that combines a dsRNA detection domain with an apoptosis induction domain completely bypasses the tricks and loopholes that viruses evolved to prevent apoptosis. Viruses don’t see DRACO coming. It completely destroys the cell the moment viral replication starts, shutting down the infection immediately while it’s still in a small population of cells. If DRACO is administered late, there is indeed more apoptosis and more inflammation, due to the larger population of affected cells. If it is administered prophylactically, before infection, viruses can’t even replicate in DRACO-treated cell populations at all, whether in vitro or in vivo. It puts a complete halt to it.
Now, with results like these, the logical thing to do would be to engage in more animal testing, experimentally confirm (or refute) the effects, and, eventually, proceed to human trials. After all, in theory, DRACO could be combined with surveillance and contact tracing to completely arrest the spread of a pathogen before it even had a chance to become a pandemic. If it worked, and if it had minimal side effects, it would have become an invaluable tool in the epidemic control toolbox.
That wasn’t what happened.
A Sidelined Cure
In 2014, Todd Rider sought $2 million in additional grant funding from the Templeton Foundation to continue his work. However, during a reorganization at the Templeton Foundation, the grant fell through, and he was left with nothing. Desperate for money, he started a pair of Indiegogo campaigns to fund his research that also failed.
Business Insider - This man's potentially huge medical breakthrough can't get funding, so he's trying something desperate
He launched an Indiegogo campaign on October 13 to raise $100,000, enough to restart his work, though just a fraction of what he truly needs. But after two months, he was only halfway there, so the campaign was recently extended.
It's impossible to know at this early stage if DRACO can do everything that Rider hopes it will — whether it will really be able to seek and destroy a wide variety of viruses inside a sick person.
And now we may never find out.
Around the same time, Ken Gabriel, an ex-DARPA and ex-Google guy, took over as head of Draper Labs.
PRWeb - Ken Gabriel, former DARPA, Google Executive, to Lead Draper Laboratory
Gabriel has been a tenured professor in both the Robotics Institute and the Department of Electrical and Computer Engineering at Carnegie Mellon University. He also served as a program manager and office director at DARPA, where he conceived and led projects that took MEMS out of the laboratory into practical applications. Earlier in his career he was a visiting professor at the University of Tokyo, a research scientist at the Naval Research Laboratory and a research principal investigator at AT&T Bell Laboratories. Gabriel’s honors include being named a Technology Pioneer by the World Economic Forum at Davos and named to the Senior Executive Service, and awarded the Carlton Tucker Prize for Excellence in Teaching from the Massachusetts Institute of Technology (MIT). Gabriel holds SM and ScD degrees in Electrical Engineering and Computer Science from the MIT.
Ken Gabriel also has links to the Wellcome Trust, who are right next door to Tavistock and have links to Sequoia Capital. He is the COO of Wellcome Leap.
Wellcome Leap - Wellcome Leap Bolsters Leadership Team, Announces Former President & CEO of Draper Ken Gabriel as Chief Operating Officer
Wellcome Leap (“Leap”), an advanced projects non-profit founded by the Wellcome Trust to accelerate innovations that benefit global human health, today announced that former U.S. Defense Advanced Research Projects Agency (DARPA) acting director Kaigham ‘Ken’ Gabriel has been appointed as Chief Operating Officer (COO) of the organization.
Ken will lead operations at Leap as the organization undertakes bold, unconventional programs and funds them at scale.With initial funding of $300 million, Leap’s programs will target complex human health challenges with the goal of achieving breakthrough scientific and technological solutions within a decade.
“Ken’s rare blend of experience across disciplines and sectors will be key to building Leap globally and delivering on our mission,” said Regina E. Dugan, CEO of Wellcome Leap. “He’s devoted to breakthrough innovation and I’m stoked to work with him.”
Whitney Webb has extensive coverage on Wellcome Leap and their transhumanist intentions.
Unlimited Hangout - A “Leap” toward Humanity’s Destruction
A UK nonprofit with ties to global corruption throughout the COVID-19 crisis as well as historical and current ties to the UK eugenics movement launched a global health-focused DARPA equivalent last year. The move went largely unnoticed by both mainstream and independent media.
The Wellcome Trust, which has arguably been second only to Bill Gates in its ability to influence events during the COVID-19 crisis and vaccination campaign, launched its own global equivalent of the Pentagon’s secretive research agency last year, officially to combat the “most pressing health challenges of our time.” Though first conceived of in 2018, this particular Wellcome Trust initiative was spun off from the Trust last May with $300 million in initial funding. It quickly attracted two former DARPA executives, who had previously served in the upper echelons of Silicon Valley, to manage and plan its portfolio of projects.
This global health DARPA, known as Wellcome Leap, seeks to achieve “breakthrough scientific and technological solutions” by or before 2030, with a focus on “complex global health challenges.” The Wellcome Trust is open about how Wellcome Leap will apply the approaches of Silicon Valley and venture capital firms to the health and life science sector. Unsurprisingly, their three current programs are poised to develop incredibly invasive tech-focused, and in some cases overtly transhumanist, medical technologies, including a program exclusively focused on using artificial intelligence (AI), mobile sensors, and wearable brain-mapping tech for children three years old and younger.
Odysee - The "Wellcome Leap" into Transhumanism - Whitney Webb on The Corbett Report
Whitney Webb of UnlimitedHangout.com joins us once again, this time to discuss her latest article, "A “Leap” toward Humanity’s Destruction." Even if you're familiar with the transhumanist agenda, what the ex-DARPA, ex-Silicon Valley old hands at the newly created Wellcome Leap are planning to do in their quest to transform the human species in the coming decade will blow your mind.
Everything ties right back into the same WEF/Club of Rome/Rockefeller transhumanist agenda; human augmentation, cattle-tagging and tracking people, pulling health data right out of their bodies, using brain data for precrime, manipulating people remotely, et cetera.
The Overclass want people to be brought onto the so-called Internet of Bodies, whether we like it or not. Mandatory vaccination is just an excuse. What they really want is unlimited leeway to mandate injections of anything, using pandemic viruses as a pretense.
It is worth reminding readers that DARPA are working on a nanoparticle-based BCI that could be used for mind control, and that this technology is advancing rapidly.
Rice University - Wireless activation of targeted brain circuits in less than one second
The researchers used genetic engineering to express a special heat-sensitive ion channel in neurons that cause flies to partially spread their wings, a common mating gesture. The researchers then injected magnetic nanoparticles that could be heated with an applied magnetic field. An overhead camera watched flies as they roamed freely about an enclosure atop an electromagnet. By changing the magnet’s field in a specified way, the researchers could heat the nanoparticles and activate the neurons. An analysis of video from the experiments showed flies with the genetic modifications assumed the wing-spread posture within approximately half a second of the magnetic field change.
Robinson said the ability to activate genetically targeted cells at precise times could be a powerful tool for studying the brain, treating disease and developing direct brain-machine communication technology.
You can’t have technology like this without a legal and civil rights framework that accounts for it, because it opens the public up to hideous abuse.
Ethicists are already very deeply concerned about the implications of neurotechnology. That’s why Rafael Yuste, the scientist whose work inspired DARPA’s BRAIN Initiative, started the Neurorights Foundation:
Jonathan Moreno is very concerned about the weaponization of neurotechnology. He wrote a book in 2012 entitled Mind Wars: Brain Science and the Military in the 21st Century. He also wrote an article on the matter that was republished in the Bulletin of the Atomic Scientists:
Bulletin of the Atomic Scientists - When neuroscience leads to neuroweapons
International law strongly proscribes the use of neuroweapons, which target the brain and central nervous system and can be chemical, biological, or toxin-producing in nature. The CWC bans the production, acquisition, stockpiling, retention, and use of chemical weapons. This relatively straightforward prohibition is undercut, however, by the convention’s provision allowing chemical agents to be used for certain law enforcement activities, like riot control. The BTWC is more sweeping in its prohibition: It bans biological agents or toxins from being used as weapons, whatever their mode or method of production. But unlike the CWC, the BTWC has no mechanism for inspecting national facilities to determine whether the prohibition is being upheld.
Neuroweapons, thus, present a challenge for both the CWC, because of its limited scope, and the BTWC, because of its lack of an inspection mechanism. In light of these limitations, it would not be surprising to see governments turn to exotic incapacitating agents in the coming decade, in an attempt to strengthen their ability to respond to threats that are unconventional, mobile, or embedded within civilian populations. Some of these neuroweapon users may be autocratic regimes interested in repressing dissent or rebellion, but as we’ve seen, the militaries of rich, democratic nations also have an interest in using nonlethal chemical weapons in attempting to confront insurgents or terrorist groups.
Attempting to counter the threat of terrorism without harming noncombatants is arguably a well-placed intention, but it paves a road to hell by threatening to undermine almost half a century of work to keep the global community engaged in upholding the ban on biological weapons, and the hard-won (if incomplete) destruction of chemical weapons stockpiles around the world. Facilities that can create nonlethal biochemical agents aren’t too different from ones that can create lethal agents—and may be identical if the only difference between a lethal and nonlethal weapon is dose.
When we bring up things like the N3 program, we’re talking about the tech to strip basic autonomy and rights from billions of people overnight and unironically turn them into Borg drones.
No, that’s not hyperbole or comical exaggeration. When I say Borg drones, I mean Borg drones.
Again, as I stated in previous articles on recent advances in biotechnology, the Chemical Weapons Convention and Biological Weapons Convention do not bar research into mind control neurotech. All you need is a bioethicist who will sign off on a project and say that it’s neither killing nor incapacitating, and therefore is not a proscribed toxin or agent.
Laws and treaties have not kept up with the pace of technological advancement in this area at all.
Rick Kiessig is the Director and CEO of the New Zealand company Kimer Med, a startup focused on reviving the DRACO concept for consumer use. He believes that pharmaceutical companies have avoided developing DRACO because it would cannibalize sales from their other, more lucrative products.
Lifespan - Rick Kiessig Discusses VTose, a Broad-Spectrum Antiviral
Dr. Todd Rider, the inventor of DRACO, said he found that government grant and NIH-type funding related to pharmaceuticals is largely limited to two broad areas: either basic research or the final step of bringing a new drug to market. However, they apparently don’t like to fund the middle part (where we are now), which involves clinical trials.
He also felt that investment from pharma companies would require showing effectiveness against commercially interesting viruses, such as herpes, which is why that was one of the goals of his 2015/2016 crowdfunding campaigns.
My view is a bit more cynical. Pharma companies have a number of drugs to treat viral illness (antivirals and others). Many of those drugs require regular use for a long period of time, because they don’t make the virus go away, they just temporarily keep the symptoms at bay as long as you continue to take them.
If you’ve been following along with our prior articles, you’d know that NIH, USAID, and DTRA are complicit in harming Americans due to their funding for EcoHealth Alliance and their GOF research which undoubtedly led to the creation of SARS-CoV-2. They also funded DRACO, but mysteriously abandoned it after it was proven to work.
One can only speculate, but from where I stand, it looks like they wanted an antidote to their forthcoming SARS-based bioweapon. Something for VIPs and officials to use in secret, while leaving the public to rot and die, suffering from long-term sequelae from COVID-19 or the side effects from the barely tested, highly toxic, autoimmunity-inducing vaccines.
It would be trivial to clandestinely produce DRACO in sufficient quantities for VIPs to use. All you need is a couple bioreactors, some chromatography columns, some E. Coli, and the DRACO plasmids to transfect into them before culturing. It’s basically all the same lab equipment needed to produce recombinant insulin. This equipment could be hidden in the corner of a bunker or a nondescript commercial building, occupying no more than several hundred square feet at the most. Huge batches sufficient for thousands of people could be manufactured even in a relatively small laboratory.
We know for a fact that DRACO is being synthesized in China, where there is ongoing research into its effectiveness in porcine reproductive and respiratory syndrome virus.
Elsevier - A high-throughput screen for genes essential for PRRSV infection using a piggyBac-based system
Double-stranded RNA activated caspase oligomerizer (DRACO) is a synthetic protein that includes three parts: protein kinase R (PKR 1–181), which can detect dsRNA; apoptotic protease-activating factor 11–97 (Apaf 11-97), which can help to selectively induce apoptosis in cells containing viral dsRNA; and protein transduction domain 4 (PTD-4), which can help to transport proteins into cells (Guo et al., 2015). In short, DRACO can rapidly kill virus-infected cells but does not affect uninfected cells. The DNA elements encoding DRACO were synthesized by General Biosystems (Anhui, China) and cloned into the expression vector pET-28a (+). The recombinant pET-28a-DRACO plasmid was identified by PCR, restriction enzyme digestion and sequencing. Then, the DRACO protein was successfully expressed and purified in vitro.
They had the cure long before they unleashed COVID-19 on us.
Not natural zoonosis. Not a lab leak. Intentional crimes against humanity.
This article is licensed under CC BY-SA 4.0. To view a copy of this license, visit http://creativecommons.org/licenses/by-sa/4.0/
You are nothing short of spectacular! I did a lot of research on DRACO, but this is not my field, and a lot is over my head. You have done a beautiful job of explaining this so we can all understand it. Thank you!
Few people understand the role Sequoia Capital plays in all of this. Sequoia provided the seed money for Silicon Valley. A limited partner provided the funding for the Wuhan virology lab. Sequoia donates millions to political campaigns. Sequoia was linked to Ghislaine Maxwell’s phony charity Terra Mar. There is this kind of evil incestuous financial relationship between Zuckerberg, Epstein, Gates, Biden, and many more.
The issue now is who would trust any company and/or doctor injecting anything into us?